Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal
- PMID: 17144779
- DOI: 10.1586/14737175.6.11.1643
Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in treating inflammation, pain and fever, but their cardiovascular, renal and gastrointestinal toxicity can result in significant morbidity and mortality to patients. Techniques for minimizing the adverse risks of NSAIDs include avoiding use of NSAIDs where possible, particularly in high-risk patients; keeping NSAID dosages low; prescribing modified-release and enteric-coated NSAIDs; prescribing cyclooxygenase-2-selective inhibitors where appropriate; monitoring for early signs of side effects; prescribing treatments designed to minimize NSAID side effects; and developing new therapeutic strategies beyond the inhibition of cyclooxygenase. All of the above strategies can be useful in reducing the risk of NSAID complications. The optimal use and management of NSAIDs involves an individualized paradigm approach to establish efficacy with optimal tolerability given the patient risk factors for adverse events.
Similar articles
-
Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.Clin Ther. 2010 Apr;32(4):667-77. doi: 10.1016/j.clinthera.2010.04.009. Clin Ther. 2010. PMID: 20435236 Review.
-
Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.Aliment Pharmacol Ther. 2009 Mar 1;29(5):481-96. doi: 10.1111/j.1365-2036.2008.03905.x. Epub 2008 Nov 27. Aliment Pharmacol Ther. 2009. PMID: 19053986
-
Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.Am J Gastroenterol. 2008 Nov;103(11):2908-18. doi: 10.1111/j.1572-0241.2008.02200.x. Epub 2008 Oct 1. Am J Gastroenterol. 2008. PMID: 18853980
-
[Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].Ned Tijdschr Geneeskd. 2007 May 12;151(19):1062-7. Ned Tijdschr Geneeskd. 2007. PMID: 17552414 Review. Dutch.
-
A review of NSAID complications: gastrointestinal and more.Lippincotts Prim Care Pract. 1999 May-Jun;3(3):305-15. Lippincotts Prim Care Pract. 1999. PMID: 10711132 Review.
Cited by
-
Nonsteroidal anti-inflammatory drug use by patients: Impact of modular educational training on pharmacists' questioning, counselling and risk assessments.Explor Res Clin Soc Pharm. 2024 Aug 20;15:100494. doi: 10.1016/j.rcsop.2024.100494. eCollection 2024 Sep. Explor Res Clin Soc Pharm. 2024. PMID: 39257532 Free PMC article.
-
Novel strategies for the treatment of inflammatory hyperalgesia.Eur J Clin Pharmacol. 2010 May;66(5):429-44. doi: 10.1007/s00228-010-0784-7. Epub 2010 Feb 13. Eur J Clin Pharmacol. 2010. PMID: 20155257 Review.
-
Discovery of GlyT2 Inhibitors Using Structure-Based Pharmacophore Screening and Selectivity Studies by FEP+ Calculations.ACS Med Chem Lett. 2019 May 22;10(6):904-910. doi: 10.1021/acsmedchemlett.9b00003. eCollection 2019 Jun 13. ACS Med Chem Lett. 2019. PMID: 31223446 Free PMC article.
-
Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib.Clin Pharmacokinet. 2008;47(11):703-20. doi: 10.2165/00003088-200847110-00002. Clin Pharmacokinet. 2008. PMID: 18840026 Review.
-
Bromamine T, a stable active bromine compound, prevents the LPS‑induced inflammatory response.Int J Mol Med. 2021 Apr;47(4):37. doi: 10.3892/ijmm.2021.4870. Epub 2021 Feb 4. Int J Mol Med. 2021. PMID: 33537817 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials